| Title: | Investigation of paraoxonase-1 genotype and enzyme-kinetic parameters in the context of cognitive impairment in Parkinson’s disease |
|---|
| Authors: | ID Petrič, Boštjan (Author)
ID Redenšek Trampuž, Sara (Author)
ID Dolžan, Vita (Author)
ID Gregorič Kramberger, Milica (Author)
ID Trošt, Maja (Author)
ID Maraković, Nikola (Author)
ID Goličnik, Marko (Author)
ID Bavec, Aljoša (Author) |
|---|
| Files: |  PDF - Presentation file, download (1,14 MB)
MD5: 45C1E6CCE7C962A97D878B5063419FCC
 URL - Source URL, visit https://www.mdpi.com/2076-3921/12/2/399
|
|---|
| Language: | English |
|---|
| Typology: | 1.01 - Original Scientific Article |
|---|
| Organization: |  UKC LJ - Ljubljana University Medical Centre
|
|---|
| Abstract: | Cognitive impairment is a common non-motor symptom of Parkinson’s disease (PD), which often progresses to PD dementia. PD patients with and without dementia may differ in certain biochemical parameters, which could thus be used as biomarkers for PD dementia. The enzyme paraoxonase 1 (PON1) has previously been investigated as a potential biomarker in the context of other types of dementia. In a cohort of PD patients, we compared a group of 89 patients with cognitive impairment with a group of 118 patients with normal cognition. We determined the kinetic parameters Km and Vmax for PON1 for the reaction with dihydrocoumarin and the genotype of four single nucleotide polymorphisms in PON1. We found that no genotype or kinetic parameter correlated significantly with cognitive impairment in PD patients. However, we observed associations between PON1 rs662 and PON1 Km (p < 10−10), between PON1 rs662 and PON1 Vmax (p = 9.33 × 10−7), and between PON1 rs705379 and PON1 Vmax (p = 2.21 × 10−10). The present study is novel in three main aspects. (1) It is the first study to investigate associations between the PON1 genotype and enzyme kinetics in a large number of subjects. (2) It is the first study to report kinetic parameters of PON1 in a large number of subjects and to use time-concentration progress curves instead of initial velocities to determine Km and Vmax in a clinical context. (3) It is also the first study to calculate enzyme-kinetic parameters in a clinical context with a new algorithm for data point removal from progress curves, dubbed iFIT. Although our results suggest that in the context of PD, there is no clinically useful correlation between cognitive status on the one hand and PON1 genetic and enzyme-kinetic parameters on the other hand, this should not discourage future investigation into PON1’s potential associations with other types of dementia. |
|---|
| Keywords: | Parkinson disease, cognitive impairment, paraoxonase 1 |
|---|
| Publication status: | Published |
|---|
| Publication version: | Version of Record |
|---|
| Year of publishing: | 2023 |
|---|
| Number of pages: | str. 1-16 |
|---|
| Numbering: | Vol. 12, iss. 2 |
|---|
| PID: | 20.500.12556/DiRROS-31482  |
|---|
| UDC: | 616.8 |
|---|
| ISSN on article: | 2076-3921 |
|---|
| DOI: | 10.3390/antiox12020399 |
|---|
| COBISS.SI-ID: | 141510403 |
|---|
| Note: |
Nasl. z nasl. zaslona;
Opis z dne 13. 2. 2023;
|
|---|
| Publication date in DiRROS: | 03.08.2026 |
|---|
| Views: | 162 |
|---|
| Downloads: | 102 |
|---|
| Metadata: |    |
|---|
|
:
|
Copy citation |
|---|
| | | | Share: |  |
|---|
Hover the mouse pointer over a document title to show the abstract or click
on the title to get all document metadata. |
